These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
598 related articles for article (PubMed ID: 12890847)
1. Drug-induced hepatotoxicity. Lee WM N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847 [No Abstract] [Full Text] [Related]
2. Avoiding hepatic injury from drugs. Kaplowitz N Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055 [No Abstract] [Full Text] [Related]
3. How can 'Hy's law' help the clinician? Senior JR Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792 [No Abstract] [Full Text] [Related]
5. Serious liver injury. Leading reason for drug removals, restrictions. Meadows M FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559 [No Abstract] [Full Text] [Related]
6. Rules and laws of drug hepatotoxicity. Kaplowitz N Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791 [No Abstract] [Full Text] [Related]
7. Structure toxicity relationships--how useful are they in predicting toxicities of new drugs? Nelson SD Adv Exp Med Biol; 2001; 500():33-43. PubMed ID: 11764962 [TBL] [Abstract][Full Text] [Related]
8. Severe but reversible hepatitis induced by troglitazone. Schiano T; Dolehide K; Hart J; Baker AL Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774 [No Abstract] [Full Text] [Related]
10. Rezulin pulled in the UK. Zurlinden J Nurs Spectr (Wash D C); 1998 May; 8(9):25. PubMed ID: 10542729 [No Abstract] [Full Text] [Related]
11. [Evaluation of thiazolidinedione derivative drugs for safety]. Kobayashi M; Iwata M Nihon Rinsho; 2001 Nov; 59(11):2228-32. PubMed ID: 11712412 [TBL] [Abstract][Full Text] [Related]
12. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients. Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275 [No Abstract] [Full Text] [Related]
14. Substituting for troglitazone (Rezulin). Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176 [No Abstract] [Full Text] [Related]
15. On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions. Stern MP Diabetes Care; 1999 May; 22(5):844-5. PubMed ID: 10332692 [No Abstract] [Full Text] [Related]
17. Troglitazone-associated hepatotoxicity treated successfully with steroids. Prendergast KA; Berg CL; Wisniewski R Ann Intern Med; 2000 Nov; 133(9):751. PubMed ID: 11074925 [No Abstract] [Full Text] [Related]
18. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Goldkind L; Laine L Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879 [TBL] [Abstract][Full Text] [Related]
19. Rezulin to be withdrawn from the market. Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272 [No Abstract] [Full Text] [Related]
20. From the Food and Drug Administration. Nightingale SL JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135 [No Abstract] [Full Text] [Related] [Next] [New Search]